Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function

Abstract

Pemigatinib dose should be reduced for patients with severe hepatic or renal impairment, and no dose adjustment is required for patients with moderate hepatic impairment or in ESRD patients undergoing HD.